Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Neil C. Robson"'
Autor:
Alberto Varas, Angeles Vicente, Manuel Ramírez, Jonathan Cebon, Eugene Maraskovsky, Rosa Sacedón, Alexander Phythian-Adams, Andrew S. MacDonald, Gustavo J. Melen, Ana Entrena, Víctor G. Martínez, Heng Wei, Tristan McAlpine, Laura Hidalgo, Neil C. Robson
Supplemental Figure S5. Effects of DMH1 on NK cells IFN-y production and killing capacity upon target cell engagement.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea73586578cb3268ac2b62eadbb77ec
https://doi.org/10.1158/0008-5472.22400543.v1
https://doi.org/10.1158/0008-5472.22400543.v1
Autor:
Alberto Varas, Angeles Vicente, Manuel Ramírez, Jonathan Cebon, Eugene Maraskovsky, Rosa Sacedón, Alexander Phythian-Adams, Andrew S. MacDonald, Gustavo J. Melen, Ana Entrena, Víctor G. Martínez, Heng Wei, Tristan McAlpine, Laura Hidalgo, Neil C. Robson
Natural killer (NK) cells are critical for innate tumor immunity due to their specialized ability to recognize and kill neoplastically transformed cells. However, NK cells require a specific set of cytokine-mediated signals to achieve optimal effecto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::736f994f42f8c4e8e3ef1aa1e9153b0d
https://doi.org/10.1158/0008-5472.c.6505613
https://doi.org/10.1158/0008-5472.c.6505613
Autor:
Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Heather M Jackson, Nektaria Dimopoulos, Philippe Guillaume, Ashley J Knights, Tamara Lowen, Neil C Robson, Sarah E Russell, Emmanuel Scotet, Ian D Davis, Eugene Maraskovsky, Jonathan Cebon, Immanuel F Luescher, Weisan Chen
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e44707 (2012)
NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8(+) T cell epitope, NY-ESO-1(88-96) (LEFYLAMPF) and
Externí odkaz:
https://doaj.org/article/146e55fe334e4f2989434de0126990e4
Publikováno v:
Current Opinion in Immunology. 22:137-144
The use of dendritic cells (DCs) for the generation of anti-tumour immunity has been the focus of a vast array of scientific and clinical studies. The ability of DCs to present protein tumour antigens (T-Ags) to CD4(+) and CD8(+) T cells is pivotal t
Autor:
Neil C Robson, Eugene Maraskovsky, Max Schnurr, Hal Braley, Stefan Endres, Amanda Shin, Denise Airey, Jonathan Cebon, Martin Orban
Publikováno v:
The Journal of Immunology. 182:1253-1259
Cancer vaccines aim to induce antitumor CTL responses, which require cross-presentation of tumor Ag to CTLs by dendritic cells (DCs). Adjuvants that facilitate cross-presentation of vaccine Ag are therefore key for inducing antitumor immunity. We pre
Autor:
Eugene Maraskovsky, Gerd Ritter, Shanshan W. Howland, Lloyd Old, Neil C Robson, Andrea Piatesi, K. Dane Wittrup, Christoph Renner, Jonathan Cebon, James A. Rakestraw
Publikováno v:
Protein Expression and Purification. 48:232-242
NY-ESO-1 is a highly immunogenic tumor antigen and a promising vaccine candidate in cancer immunotherapy. Access to purified protein both for vaccine formulations and for monitoring antigen-specific immune responses is vital to vaccine development. C
Publikováno v:
Immunology. 110:95-104
Immune stimulating complexes (ISCOMs) containing the saponin adjuvant Quil A are vaccine adjuvants that promote a wide range of immune responses in vivo, including delayed-type hypersensitivity (DTH) and the secretion of both T helper 1 (Th1) and Th2
Publikováno v:
Immunology. 109:374-383
Immune stimulating complexes (ISCOMS) containing the saponin adjuvant Quil A are vaccine adjuvants that induce a wide range of immune responses in vivo, including strong class I major histocompatibility complex (MHC) -restricted cytotoxic T-lymphocyt
Autor:
Angeles Vicente, Manuel Ramírez, Jonathan Cebon, Heng Wei, Ana Entrena, Alberto Varas, Neil C Robson, Víctor G. Martínez, Gustavo J. Melen, Laura Hidalgo, Andrew S. MacDonald, Rosa Sacedón, Tristan McAlpine, Eugene Maraskovsky, Alexander T. Phythian-Adams
Natural killer (NK) cells are critical for innate tumor immunity due to their specialized ability to recognize and kill neoplastically transformed cells. However, NK cells require a specific set of cytokine-mediated signals to achieve optimal effecto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2905a0d6127340f3fbe031c21b1f91e
https://europepmc.org/articles/PMC4167038/
https://europepmc.org/articles/PMC4167038/
Autor:
Tamara Lowen, Nicole A. Mifsud, Kun Xiao, Sara Oveissi, Jonathan Cebon, Eugene Maraskovsky, Heather Jackson, Kok-fei Chan, Immanuel F. Luescher, Ian D. Davis, Philippe Guillaume, Ashley Knights, Sarah E Russell, Rona Y Zhao, Weisan Chen, Nektaria Dimopoulos, Neil C Robson, Emmanuel Scotet
Publikováno v:
Plos One, vol. 7, no. 9, pp. e44707
PLoS ONE, Vol 7, Iss 9, p e44707 (2012)
PLoS ONE
PLoS ONE, Vol 7, Iss 9, p e44707 (2012)
PLoS ONE
NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8+T cell epitope, NY-ESO-188–96 (LEFYLAMPF) and co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74de3de0976e6474a4ee41e9d1647ab
https://serval.unil.ch/resource/serval:BIB_7E77F0F308BA.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_7E77F0F308BA.P001/REF.pdf